Mechanism of action of nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome in liver diseases
10.3969/j.issn.1001-5256.2022.04.041
- VernacularTitle:核苷酸结合寡聚化结构域样受体蛋白3炎性小体在肝脏疾病中的作用机制
- Author:
Yan YANG
1
;
Feilin GE
2
;
Qian HUANG
3
;
Xinyue ZHANG
1
;
Rui ZENG
3
;
Xiaohe XIAO
4
;
Zhaofang BAI
4
;
Qin SUN
1
,
5
,
6
Author Information
1. School of Integrated Traditional Chinese and Western Medicine, Southwest Medical University, Luzhou, Sichuan 646000, China
2. School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China
3. School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China
4. China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
5. Drug Research Center of Integrated Traditional Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China
6. National Traditional Chinese Medicine Clinical Research Base, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China
- Publication Type:Reviews
- Keywords:
NLRP3 Inflammasome;
Liver Diseases;
Immunity, Innate
- From:
Journal of Clinical Hepatology
2022;38(4):942-946
- CountryChina
- Language:Chinese
-
Abstract:
Inflammasomes play an important role in the innate immunity of the liver; however, the excessive activation of inflammasomes can lead to liver inflammation and injury. The mechanism of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome-mediated liver injury has been extensively studied. Related studies have shown that the development of various liver diseases may be associated with the excessive activation of inflammasomes, especially NLRP3 inflammasome. This article reviews inflammasomes, the activation mechanism of NLRP3 inflammasome, and the role of NLRP3 inflammasome in different liver diseases, so as to provide a reference for the treatment targets of liver diseases from the perspective of NLRP3 inflammasome.
